Spruce Biosciences (SPRB) Projected to Post Quarterly Earnings on Thursday

by · The Markets Daily

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) is projected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Spruce Biosciences to post earnings of ($9.1575) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 9, 2026 at 7:00 AM ET.

Spruce Biosciences Stock Up 11.2%

NASDAQ SPRB opened at $62.11 on Tuesday. The company has a market capitalization of $66.46 million, a price-to-earnings ratio of -0.73 and a beta of 3.62. Spruce Biosciences has a twelve month low of $4.28 and a twelve month high of $240.00. The stock has a fifty day simple moving average of $72.15 and a 200 day simple moving average of $75.55.

Analysts Set New Price Targets

SPRB has been the topic of a number of analyst reports. Wall Street Zen lowered Spruce Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, December 27th. Citizens Jmp set a $259.00 price objective on Spruce Biosciences in a research note on Tuesday, November 11th. Leerink Partners upgraded Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $160.00 target price on the stock in a report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Spruce Biosciences in a research report on Monday, December 29th. Finally, Citigroup restated a “market perform” rating on shares of Spruce Biosciences in a report on Tuesday, November 11th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $187.90.

View Our Latest Analysis on Spruce Biosciences

Hedge Funds Weigh In On Spruce Biosciences

Institutional investors have recently added to or reduced their stakes in the business. SkyView Investment Advisors LLC bought a new position in shares of Spruce Biosciences during the 4th quarter worth approximately $261,000. State Street Corp acquired a new position in shares of Spruce Biosciences during the 4th quarter valued at $558,000. Superstring Capital Management LP acquired a new position in shares of Spruce Biosciences during the 4th quarter valued at $1,057,000. Geode Capital Management LLC bought a new position in Spruce Biosciences during the fourth quarter worth $1,109,000. Finally, Caligan Partners LP bought a new position in Spruce Biosciences during the fourth quarter worth $1,787,000. 91.71% of the stock is owned by institutional investors and hedge funds.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.

Recommended Stories